SBBP News and Press, Strongbridge Biopharma plc From 09/08/20

~ Company Reported Positive and Statistically Significant Top-Line Results from the Pivotal Phase 3 LOGICS Study of RECORLEV ® (levoketoconazole) for the Treatment of Endogenous Cushing’s Syndrome; To View the Complete Earlier Announcement, Visit the Company’s Website ~...

Crinetics Pharmaceuticals (NASDAQ: CRNX ) announces that a presentation of its orally available small molecule adrenocorticotropic hormone (ACTH) antagonist was selected for a late-breaking session a the virtual European Congress of Endocrinology on September 8. More news on: Crinetics...

Stonebridge Biopharma plc ( SBBP ) is nearing its transformational value inflection point with the expected release of Recorlev's Phase 3 topline data for Cushing's disease due next month (September 2020). If Recorlev's Phase 3 topline data is good enough, SBBP will file a NDA in Q1 2021 with ...

Strongbridge Biopharma plc (SBBP) Q2 2020 Earnings Conference Call August 4, 2020 08:30 am ET Company Participants Lindsay Rocco - Elixir Health, Public Relations John Johnson - Chief Executive Officer Fred Cohen - Chief Medical Officer Rob Lutz - Chief Financial Officer Scot...

The following slide deck was published by Strongbridge Biopharma plc in conjunction with their 2020 Q2 earnings Read more ...

Strongbridge Biopharma (NASDAQ: SBBP ) : Q2 Non-GAAP EPS of -$0.12 beats by $0.08 ; GAAP EPS of -$0.32 misses by $0.08 . More news on: Strongbridge Biopharma plc, Earnings news and commentary, Healthcare stocks news, , Read more ...

~ Reports KEVEYIS ® (dichlorphenamide) Second Quarter 2020 Revenue of $7.8 Million, a 28 Percent Increase Compared to $6.1 Million During Second Quarter of 2019 ~ ~ Company Expects to Report Top-Line Results from the Phase 3 LOGICS Study of RECORLEV™ (levoketoconazole) in...

DUBLIN, Ireland and TREVOSE, Pa., July 28, 2020 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced t...

DUBLIN, Ireland and TREVOSE, Pa., July 07, 2020 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced t...

DUBLIN, Ireland and TREVOSE, Pa., July 01, 2020 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced t...